Work

381: Sildenafil (Revatio) Therapy in Chronic Graft Versus Host Disease (cGVHD): Improvement in Pulmonary cGVHD Symptoms

Year: 2008

Type: article

Abstract: Sildenafil (Revatio) has been used in patients with primary pulmonary hypertension but its impact on the post allogeneic transplant recipents with chronic lung graft versus host disease (cGVHD) has not been well characterized. We have noted significant improvement in an index case with peripheral acrocyanosis and dyspnea. Since then we have treated 3 more patients with Revatio as detailed in this report.Tabled 1Cardiopulmonary Studies before and after SildenafilPatient #PFT: Pre-RevatioPFT: Post-RevatioECHO-Pre-RevatioECHO-Post-Revatio12.78 L2.23 LNormalNA22.52 L1.16 L73%NA32.24 L2.49 L62%60%41.66 L1.55 LNormalNAPulmonary artery pressure was 27, <30 and 50 mm Hg in patients 1, 2, 3. Open table in a new tab Sildenafil (Revatio) has been used in patients with primary pulmonary hypertension but its impact on the post allogeneic transplant recipents with chronic lung graft versus host disease (cGVHD) has not been well characterized. We have noted significant improvement in an index case with peripheral acrocyanosis and dyspnea. Since then we have treated 3 more patients with Revatio as detailed in this report. Pulmonary artery pressure was 27, <30 and 50 mm Hg in patients 1, 2, 3.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2007.12.391